Neovacs SA is a biotechnology company focused on developing immunotherapeutics for the treatment of autoimmune and inflammatory diseases. Their corporate philosophy centers around innovation, scientific excellence, and advancing patient care. Neovacs believes in delivering safe and effective solutions through strategic collaborations and rigorous research. By prioritizing patient well-being, Neovacs aims to bring breakthrough treatments to market that have the potential to improve the lives of individuals suffering from chronic conditions. With a strong emphasis on scientific advancement and a commitment to corporate values, Neovacs SA stands as a leader in the field of immunotherapy.

Neovacs SA is primarily present in France and South Korea.

Neovacs SA has achieved significant milestones in its operational history. Some notable accomplishments include the successful initiation of clinical trials for its lead product, IFNalpha-Kinoïde, which aims to treat lupus and dermatomyositis. Neovacs SA has also secured partnerships with prestigious organizations, such as the Lupus Foundation of America, enhancing its credibility in the industry. The company's innovative technology and research efforts have garnered recognition, leading to several patents being granted. Furthermore, Neovacs SA has expanded its global presence through strategic collaborations with international pharmaceutical companies, reinforcing its position as a key player in the field of immunotherapy.

Neovacs SA is a biotechnology company that specializes in developing immunotherapies for the treatment of autoimmune diseases and cancer. Founded in 1993, the company is headquartered in France. Neovacs SA focuses on leveraging its unique technology platform, Kinoids, for the production of therapeutic vaccines. These vaccines aim to stimulate the immune system to target specific antigens associated with diseases such as Lupus and Type 1 Diabetes. With a dedicated team of scientists and researchers, Neovacs SA is committed to advancing innovative treatment options and improving patient outcomes. Through its continuous efforts, the company strives to make a significant impact in the field of immunotherapy.

The main competitors of Neovacs SA in the market are companies such as GlaxoSmithKline, Novartis, and Sanofi.

Neovacs SA is primarily active in the pharmaceutical and biotechnology industries.

Neovacs SA is a biotechnology company specializing in the development of immunotherapeutic drugs. Its business model revolves around the discovery, development, and commercialization of innovative treatments for autoimmune diseases, such as lupus and dermatomyositis. By utilizing its proprietary technology, Neovacs aims to target specific proteins implicated in these diseases, ultimately offering patients safer and more effective treatment options. With a focus on advancing its pipeline of potential therapies, Neovacs aims to address significant unmet medical needs, improving the quality of life for individuals affected by autoimmune conditions.

Raportul preț/beneficiu (KGV) pentru Neovacs nu poate fi calculat în prezent.

KUV nu poate fi calculat în prezent pentru Neovacs.

Scorul de calitate AlleAktien pentru Neovacs este 4/10.

Cifra de afaceri nu poate fi calculată în prezent pentru Neovacs.

Profitul nu poate fi calculat în prezent pentru Neovacs.

The French company Neovacs SA is a leading biotechnology company specializing in the development of immunotherapies. It is divided into several business areas, all of which contribute in different ways to the treatment of autoimmune diseases. Neovacs SA's main focus is on developing vaccines for autoimmune diseases. The main products include the IFNα-Kinoid vaccine and the VEGF-Kinoid vaccine. Both vaccines aim to reprogram the body's immune system to only attack diseased cells and spare healthy cells. Neovacs SA's IFNα-Kinoid vaccine is currently being developed for the treatment of lupus erythematosus and dermatomyositis. It is a novel therapy based on the idea that the vaccine trains the immune system of lupus patients to produce antibodies against IFNα. These antibodies block the effects of IFNα, which is responsible for harmful immune reactions in lupus patients. Neovacs SA's VEGF-Kinoid vaccine is currently being developed for the treatment of cancer. It aims to block the growth of blood vessels needed for the nourishment of tumor cells. The vaccine activates the body's immune system to specifically target the blood vessels and inhibit tumor growth. In addition to vaccine development, the company also manufactures polypeptide-based immunomodulators. These are responsible for regulating the immune system and preparing it to fight diseases. The main products in this area include the TNF-Kinoid and IL-4/IL-13 Kinoid. Both target molecules play an important role in the development of chronic inflammation associated with autoimmune diseases. Neovacs SA also has a clinical research division focused on the development of new immunotherapeutic products. Various technologies such as peptide design and antibody engineering are used to develop new medications that selectively impact the immune system. Additionally, Neovacs SA offers a wide range of services in the field of biotechnological research. This includes the development of production processes, analytical method development, and toxicity studies. Overall, Neovacs SA is a leading provider of immunotherapeutic products and services targeting the treatment of autoimmune diseases. With its wide range of products and expertise in this field, the company is well-positioned to meet future challenges in the biotechnology industry.

Neovacs distribuie un dividend de 0 EUR în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Neovacs sau compania nu distribuie dividende.

Codul ISIN pentru Neovacs este FR0004032746.

Codul WKN al Neovacs este A1CVKR.

Ticker-ul pentru Neovacs este ALNEV.PA.

În ultimele 12 luni, Neovacs a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, Neovacs va plăti probabil un dividend de 0 EUR.

Randamentul dividendelor pentru Neovacs este în prezent de .

Neovacs plătește un dividend trimestrial. Acesta este distribuit în lunile .

Neovacs a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 EUR. Acest lucru corespunde unei randamente a dividendelor de 0 %.

Neovacs este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Neovacs de la 18.12.2024 în valoare de 0 EUR, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 18.12.2024.

Ultima plată a dividendului a fost efectuată la 18.12.2024.

În anul 2023, Neovacs a distribuit 0 EUR sub formă de dividende.

Dividendele de la Neovacs sunt distribuite în EUR.